Advanced Weight Management
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that represents the most advanced approach to metabolic weight management. Clinical trials have shown it achieves greater weight reduction than single-target therapies, with results from the SURMOUNT program demonstrating exceptional efficacy.
Key research findings
Average weight reduction of 20.9% at the highest dose in the SURMOUNT-1 trial
Head-to-head trial (SURMOUNT-5) showed 20.2% weight loss vs 13.7% with semaglutide
Over one-third of participants achieved 25% or greater weight loss
Significant improvements in metabolic markers including blood sugar and blood pressure
Dual mechanism targeting both GIP and GLP-1 receptors for enhanced efficacy
Published research & clinical studies
STUDY 1
SURMOUNT-1 — Tirzepatide for Treatment of Obesity
New England Journal of Medicine, 2022
Phase 3 trial (n=2,539) demonstrating up to 22.5% weight reduction with tirzepatide vs 2.4% placebo.
STUDY 2
SURMOUNT-5 — Tirzepatide vs Semaglutide Head-to-Head
New England Journal of Medicine, 2024
Direct comparison trial showing tirzepatide achieved 20.2% vs semaglutide's 13.7% weight loss at 72 weeks.
STUDY 3
SURMOUNT-2 — Tirzepatide for Weight Management in Type 2 Diabetes
Lancet, 2023
Phase 3 trial in patients with obesity and type 2 diabetes showing significant weight loss and glycemic improvement.
STUDY 4
SURMOUNT-3 — Tirzepatide After Intensive Lifestyle Intervention
Nature Medicine, 2024
Trial evaluating tirzepatide added to intensive lifestyle intervention for sustained weight management.
STUDY 5
SURMOUNT-4 — Tirzepatide Withdrawal and Weight Regain
JAMA, 2024
Study examining weight trajectory after tirzepatide continuation vs switching to placebo.
Research disclaimer: The studies referenced above are provided for educational purposes only. They represent published scientific research and do not constitute medical advice, treatment recommendations, or endorsement of any specific therapy. Velacore Health does not provide medical services or prescribe medications. All decisions regarding peptide therapy are made solely by independent, licensed healthcare providers. Always consult with your healthcare provider before considering any therapy.